(Q35775292)

10 August 2017

1 reference

title

Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine (English)

1 reference

10 August 2017

1 reference

1 reference

Richard B Lipton

1 reference

10 August 2017

Peter J Goadsby

1 reference

10 August 2017

David Dodick

1 reference

10 August 2017

Stephen D. Silberstein

object named as

Stephen Silberstein

1 reference

Antoinette MaassenVanDenBrink

10 August 2017

object named as

Antoinette MaassenVanDenBrink

1 reference

10 August 2017

Timothy R Smith

1 reference

10 August 2017

Vincent Martin

1 reference

10 August 2017

Vasilios Papademetriou

1 reference

10 August 2017

Wayne Rosamond

1 reference

10 August 2017

Hassan Loutfi

1 reference

10 August 2017

K Michael Welch

1 reference

10 August 2017

Steven Hahn

1 reference

10 August 2017

Susan Hutchinson

1 reference

10 August 2017

David Matchar

1 reference

10 August 2017

R Allan Purdy

1 reference

10 August 2017

Jane Saiers

1 reference

10 August 2017

Triptan Cardiovascular Safety Expert Panel

1 reference

10 August 2017

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

414-425

1 reference

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

The global burden of disease study: implications for neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Migraine--current understanding and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Migraine diagnosis and treatment: results from the American Migraine Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Migraine and stroke in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

The relationship of migraine and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Oral almotriptan in the treatment of migraine: safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Tolerability and efficacy of almotriptan in the long-term treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

5-HT1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Migraine and angina pectoris by coronary artery spasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Is chest pain after sumatriptan oesophageal in origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

An association between migraine and cutaneous allodynia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Contribution of central sensitisation to the development of non-cardiac chest pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1526-4610.2004.04078.X

10.1111/J.1526-4610.2004.04078.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference